Cancer immunotherapy has produced some of medicine’s most dramatic success stories over the past decade. But for every patient whose tumors vanish, several others see little or no benefit. One class of drugs in particular, called CD40 agonist antibodies, promised to supercharge the immune system’s ability to hunt and destroy cancer cells. For more than 20 years, that promise went unfulfilled. Clinical trials produced modest results and dangerous side effects. The drugs seemed destined for the shelf. Then a team at Rockefeller University did two things differently: they redesigned the antibody from the ground up, and they changed how it enters the body. Instead of infusing it into the bloodstream, they injected it directly into a single tumor. What happened next stunned the researchers. Tumors across the body began to shrink. In two patients with aggressive, metastatic cancers, every detectable tumor disappeared entirely.
CD40 Agonists: Two Decades of Disappointment
CD40 is a receptor found on the surface of immune cells, particularly antigen-presenting cells like dendritic cells, B cells, and macrophages. When CD40 gets activated, it sends a powerful signal to the immune system: wake up, find the threat, and attack.
Scientists recognized early on that activating CD40 could trigger a strong anti-tumor immune response. Laboratory experiments showed that CD40 agonist antibodies could help generate cancer-killing T cells and produce meaningful tumor regression in animal models. The concept was sound. The execution was not.
Starting in the early 2000s, multiple CD40 agonist antibodies entered clinical trials. The results were consistently disappointing. Even at low doses, the drugs caused widespread inflammation, dangerously low platelet counts, and liver damage. Because CD40 receptors exist on immune cells throughout the body, infusing the drug into the bloodstream activated the immune system everywhere at once, producing toxic side effects that limited how much drug patients could safely receive.
At higher doses, the toxicity worsened. At lower doses, the anti-tumor effect was too weak to matter. CD40 agonist therapy appeared stuck in a dead zone where it was either too dangerous or too feeble to help.
Two Changes That Rewrote the Playbook
In 2018, Jeffrey V. Ravetch and his team at Rockefeller University published findings that identified two specific problems with existing CD40 drugs and proposed solutions for both.
First, they redesigned the antibody itself. The original CD40 agonist (known as CP-870,893) was an IgG2 antibody. Ravetch’s team switched it to an IgG1 framework and introduced five precise mutations that increased its binding affinity to a specific immune receptor called FcΞ³RIIB. That receptor acts as a crosslinking platform that helps CD40 cluster properly on cell surfaces, which amplifies the activation signal. Laboratory testing showed the redesigned antibody, called 2141-V11, was about 10 times more effective at triggering an immune attack against tumors than previous versions.
Second, they changed the delivery method. Instead of putting the drug into the bloodstream, where it would activate CD40 receptors on immune cells throughout the body, they injected it directly into tumors. In their humanized mouse models, intratumoral injection produced strong anti-tumor responses with only mild toxicity, avoiding the liver damage and platelet crashes that had plagued earlier clinical trials.
These two changes, a better antibody and a smarter delivery route, set the stage for the first human test.
Twelve Patients, Six Responses, Two Complete Remissions
Results from the Phase 1 clinical trial of 2141-V11 were published in the journal Cancer Cell. The study enrolled 12 patients with metastatic cancers that had spread to the skin, subcutaneous tissue, or lymph nodes, making them accessible for direct injection. Seven patients had breast cancer. Three had melanoma. Two had renal cell carcinoma.
These were not early-stage patients. The median time since their original diagnosis was five years. They had received a median of five previous treatment lines. Most had already tried chemotherapy, immunotherapy, or both without lasting success.
Researchers injected 2141-V11 directly into one or more accessible tumors at escalating dose levels across four groups. The primary goal was safety: determining a safe dose and identifying side effects.
On that front, the results were encouraging. Ten of 12 patients experienced some type of adverse event, but none were severe (grade 3 or above) treatment-related events. Common side effects included temporary fever, chills, and injection-site reactions, mostly at higher doses. No patients experienced the platelet crashes or liver damage that had derailed previous CD40 drugs.
The anti-tumor results went far beyond what a Phase 1 safety trial typically produces. Among 11 patients evaluable for response, tumors shrank in six. Four patients achieved disease control. Two patients experienced complete remission, meaning every detectable tumor in their bodies disappeared.
One Injection, Tumors Vanishing Everywhere
The most remarkable finding was not just that tumors shrank. It was where they shrank. Researchers injected the drug into accessible tumors on the skin. But tumors at distant sites, ones that never received a single drop of the drug, also began to disappear.
Ravetch described the result as dramatic and unexpected. Injecting locally but seeing a systemic response is not something seen very often in any clinical treatment, he said.
The first complete responder was an 89-year-old woman with recurrent melanoma. She had dozens of metastatic tumors on her left leg and foot. Researchers injected just one tumor on her upper thigh. Over multiple treatment cycles, all the other tumors, including ones on her distant left foot, flattened and disappeared. She remained in remission for nearly 28 months before a recurrence appeared in her toe.
The second complete responder was a 67-year-old woman with stage IV hormone receptor-positive breast cancer that had spread to her skin, axillary lymph nodes, and liver. She had already failed 14 previous lines of therapy. Researchers injected her skin tumors, splitting doses between two locations. By cycle 2, her cutaneous lesions were visibly shrinking. By cycles 4 and 5, all skin tumors had resolved. By cycle 7, her liver metastases had vanished on follow-up imaging. Her tumor markers in the blood normalized completely. She maintained remission for 7.1 months before recurrence.
How One Injection Triggers a Full-Body Immune Attack
To understand why untreated tumors were disappearing, researchers examined tissue samples from both responding and non-responding patients. What they found inside the treated tumors surprised even the scientists.
Juan Osorio, the study’s first author and a medical oncologist at Memorial Sloan Kettering Cancer Center, described the transformation: the tumors became full of immune cells, including different types of dendritic cells, T cells, and mature B cells, that formed aggregates resembling something like a lymph node. The drug essentially replaced the tumor with organized immune structures.
These structures are called tertiary lymphoid structures (TLS). In normal biology, immune responses are coordinated in lymph nodes. TLS are essentially improvised lymph nodes that form inside or near tumors, creating local hubs where the immune system can recognize cancer cells, activate T cells, and launch a targeted attack.
TLS has been linked to better outcomes in cancer treatment across multiple studies. But what made this finding unusual is that the drug appeared to actively create TLS where none existed before. Before treatment, no TLS was present. After treatment with 2141-V11, mature TLS filled the injected tumors of responding patients.
Even more striking, researchers detected TLS forming in tumors that were never injected with the drug. Once the immune system identified cancer cells at the injected site, immune cells migrated to distant tumor locations and built new attack bases there as well.
Osorio explained the process: once the immune system identifies the cancer cells, immune cells migrate to the non-injected tumor sites and mount a response.
The Immune System Learns and Remembers
Beyond the immediate tumor destruction, the treatment appeared to create lasting immune memory. In mouse models, animals that achieved complete remission after 2141-V11 treatment were rechallenged with five times the original tumor dose 90 days later. Unlike untreated mice, the primed animals rejected the new tumors completely, showing their immune systems had learned to recognize and attack those cancer cells on sight.
In the melanoma patient, remission lasted nearly 28 months, far beyond the treatment period itself. That durability suggests the immune system was maintaining surveillance long after the drug had cleared.
Blood analysis from responding patients revealed significant expansion of effector CD8+ T cells, the primary cancer-killing immune cells. These T cells were clonally expanded, meaning the immune system had identified specific cancer targets and mass-produced T cells designed to attack them. Complete responders also showed higher proportions of clonal CD8+ T cells at baseline, before treatment even began, hinting that some patients may be better primed to respond.
Why Some Patients Respond and Others Do Not
Not every patient benefited from the treatment. Six of 11 evaluable patients saw tumor shrinkage, but only two achieved complete remission. Understanding why some patients respond while others do not is now the central question driving future research.
The two complete responders shared a common trait: they entered the trial with higher clonality of CD8+ T cells. Their immune systems already had a head start in recognizing cancer, and 2141-V11 amplified that existing advantage.
Patients who did not respond showed reduced immune infiltration in their tumors after treatment and lacked TLS formation. Without those organized immune structures, the drug could not establish the local immune environment needed to generate a systemic attack.
Osorio framed the challenge facing the field: as a general rule, only 25 to 30 percent of patients respond to immunotherapy. The biggest challenge is determining which patients will benefit and how to convert non-responders into responders.
Biomarker research from the ongoing larger trials may help answer those questions. If scientists can identify immune signatures that predict who will respond, doctors could select patients more effectively or combine 2141-V11 with other treatments to overcome resistance.
Larger Trials Are Already Underway
The promising Phase 1 results have fueled several follow-up studies. Ravetch’s group is now collaborating with scientists at Memorial Sloan Kettering Cancer Center and Duke University to test 2141-V11 in larger, more defined patient populations.
Phase 1 and Phase 2 trials are currently evaluating the drug against several difficult-to-treat cancers, including bladder cancer, prostate cancer, and glioblastoma (the deadliest form of brain cancer). Nearly 200 patients are participating across these studies.
Early data from the bladder cancer trial, where the drug is delivered directly into the bladder, is showing similar safety and preliminary activity, suggesting the approach may work across multiple tumor types, not just cancers accessible through the skin.
If larger trials confirm the early results, 2141-V11 could represent a fundamentally new way to deliver cancer immunotherapy: treat one tumor, train the immune system, and let it hunt down cancer throughout the body.
My Personal RX on Supporting Your Immune System During and After Cancer Treatment
Cancer treatment takes a heavy toll on your body, and immune health plays a central role in both fighting disease and recovering from treatment. Whether you are going through active treatment or focused on prevention, supporting your immune system through nutrition, sleep, and stress management gives your body the best chance to respond. Here is what I recommend:
- Prioritize Deep, Restorative Sleep: Your immune system produces critical cancer-fighting cells, including T cells and natural killer cells, during deep sleep. Sleep Max combines magnesium, GABA, 5-HTP, and taurine to promote restorative REM sleep so your body can maintain strong immune defenses overnight.
- Know Your Supplement Gaps: Cancer treatment and aging both deplete key nutrients that your immune system depends on. Download my free guide, The 7 Supplements You Can’t Live Without, to learn which supplements support immune function, which “healthy” foods may be misleading you, and how to identify quality products.
- Move Your Body for at Least 30 Minutes Daily: Moderate exercise improves immune cell circulation, reduces inflammation, and supports recovery from treatment. Walking, swimming, yoga, and light resistance training are all effective and well-tolerated options during and after cancer treatment.
- Manage Chronic Stress: Prolonged stress raises cortisol, which suppresses both innate and adaptive immune responses. Practice daily breathwork, meditation, or time in nature to keep your stress hormones in check and your immune system responsive.
- Eat a Colorful, Plant-Rich Diet: Fruits, vegetables, nuts, seeds, and whole grains provide the vitamins, minerals, and phytochemicals your immune cells need to function at their best. Aim for at least five servings of produce per day and rotate colors to maximize nutrient diversity.
- Stay Hydrated: Proper hydration supports lymphatic circulation, which is essential for moving immune cells throughout your body. Aim for at least eight glasses of water per day.
- Reduce Sugar and Processed Food: High-sugar diets promote inflammation and can suppress immune function. Replace processed snacks and sugary drinks with whole, nutrient-dense alternatives.
- Stay Connected to Your Medical Team: Regular checkups, imaging, and blood work allow your doctors to monitor your immune health and catch any changes early. Open communication with your oncologist or primary care provider is essential for making informed treatment decisions.
Source: Osorio, J. C., Knorr, D. A., Weitzenfeld, P., Blanchard, L., Yao, N., Baez, M., Sevilla, C., DiLillo, M., Rahman, J., Sharma, V. P., Bromberg, J., Postow, M. A., Ariyan, C., Robson, M. E., & Ravetch, J. V. (2025). Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell, 43(10), 1902-1916.e9. https://doi.org/10.1016/j.ccell.2025.07.013
Subscribe to Ask Dr. Nandi YouTube Channel
